# ATNM (Actinium Pharmaceuticals, Inc.) - SEC EDGAR Financial Statements

> Actinium Pharmaceuticals, Inc. reported $90K in revenue and net income of $10.60M for the fiscal year ended December 31, 2025, with a 10140.0% operating margin.

- Canonical: https://convexityos.com/fundamentals/ATNM
- Markdown: https://convexityos.com/fundamentals/ATNM.md
- SEC CIK: 0001388320
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:53 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001388320&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | $90K | Dec 31, 2025 |
| Operating Income | FY 2025 | $9.13M | 10140.0% margin |
| Net Income | FY 2025 | $10.60M | 11773.3% net margin |
| Diluted EPS | FY 2025 | $0.34 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$24.68M | -27426.7% FCF margin |
| Cash & ST Investments | Sep 30, 2026 | $28.68M | Total debt: $1.16M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $90K | -- | $81K | $1.03M | $1.14M | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | $900K | -- | -- | -- | -- | -- |
| **Gross Profit** | -- | -- | -- | -- | $244K | -- | -- | -- | -- | -- |
| Research & Development | $21.12M | $30.05M | $38.67M | $23.14M | $18.03M | $16.09M | $16.55M | $17.09M | $17.72M | $17.83M |
| Total Operating Expenses | $36.34M | $42.12M | $52.00M | $35.13M | $26.11M | $22.39M | $22.07M | $23.83M | $26.91M | $26.85M |
| **Operating Income** | -$36.25M | -$42.12M | -$51.92M | -$34.10M | -$24.96M | -$22.39M | -$22.07M | -$23.83M | -$26.91M | -$26.85M |
| **EBITDA** | -$36.07M | -$41.92M | -$51.71M | -$33.41M | -$24.44M | -$21.95M | -$21.65M | -$23.78M | -$26.85M | -$26.77M |
| Interest Income | $2.36M | $3.88M | $3.10M | -- | -- | -- | -- | -- | -- | -- |
| Interest Expense | -- | -- | -- | -- | -- | -- | -- | -- | -- | $5.0K |
| **Net Income** | -$33.89M | -$38.24M | -$48.82M | -$33.02M | -$24.77M | -$22.21M | -$21.90M | -$23.65M | -$26.60M | -$24.32M |
| Basic EPS | -$1.09 | -$1.27 | -$1.83 | -$1.37 | -$1.20 | -$1.83 | -$4.40 | -$0.22 | -$0.40 | -$0.50 |
| **Diluted EPS** | -$1.09 | -$1.27 | -$1.83 | -$1.37 | -$1.20 | -$1.83 | -$4.40 | -$0.22 | -$0.40 | -$0.50 |
| Basic Shares Outstanding | 31.2M | 30.1M | 26.6M | 24.1M | 20.6M | 12.1M | 5.0M | 106.0M | 66.7M | 48.5M |
| Diluted Shares Outstanding | 31.2M | 30.1M | 26.6M | 24.1M | 20.6M | 12.1M | 5.0M | 106.0M | 66.7M | 48.5M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | -- | $35.00M | -- | -- | $90K | -- | -- | -- |
| Research & Development | $4.71M | $5.38M | $4.20M | $4.30M | $4.25M | $4.88M | $7.70M | $4.81M |
| Total Operating Expenses | $6.12M | $7.43M | $5.90M | $6.41M | $5.78M | $7.50M | $16.64M | $7.50M |
| **Operating Income** | -$6.12M | $27.57M | -$5.90M | -$6.41M | -$5.69M | -$7.50M | -$16.64M | -$7.50M |
| **EBITDA** | -$5.90M | $28.00M | -$5.87M | -$6.86M | -$5.49M | -$7.14M | -$16.59M | -$7.92M |
| Interest Income | $279K | $336K | $381K | $474K | $561K | $625K | $700K | $853K |
| **Net Income** | -$5.84M | $27.90M | -$5.52M | -$5.94M | -$5.13M | -$6.88M | -$15.94M | -$6.65M |
| Basic EPS | -$0.19 | $0.89 | -$0.18 | -- | -$0.16 | -$0.22 | -$0.51 | -- |
| **Diluted EPS** | -$0.19 | $0.89 | -$0.18 | -- | -$0.16 | -$0.22 | -$0.51 | -- |
| Basic Shares Outstanding | 31.4M | 31.4M | 31.2M | -- | 31.2M | 31.2M | 31.2M | -- |
| Diluted Shares Outstanding | 31.4M | 31.4M | 31.2M | -- | 31.2M | 31.2M | 31.2M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $48.00M | $72.90M | $76.68M | $108.9M | $77.83M | $63.56M | $9.25M | $13.67M | $17.40M | $20.52M |
| **Cash & Short-Term Investments** | $48.00M | $72.90M | $76.68M | $108.9M | $77.83M | $63.56M | $9.25M | $13.67M | $17.40M | $20.52M |
| Other Current Assets | $168K | $357K | $226K | $65K | -- | -- | -- | -- | -- | -- |
| **Total Current Assets** | $49.38M | $74.51M | $78.26M | $110.9M | $79.75M | $64.92M | $10.09M | $14.33M | $17.84M | $22.39M |
| Property, Plant & Equipment, Net | $295K | $364K | $550K | $604K | $340K | $312K | $113K | $119K | $57K | $89K |
| Goodwill | -- | -- | -- | -- | -- | -- | -- | -- | -- | $100K |
| **Total Non-Current Assets** | $2.39M | $2.39M | $3.18M | $3.25M | $639K | $1.47M | $1.58M | $560K | $498K | $138K |
| **Total Assets** | $51.77M | $76.90M | $81.44M | $114.2M | $80.39M | $66.40M | $11.67M | $14.89M | $18.34M | $22.53M |
| Deferred Revenue (Current) | -- | -- | -- | -- | $1.00M | -- | -- | -- | -- | -- |
| Other Current Liabilities | -- | -- | -- | -- | $998K | -- | -- | -- | -- | -- |
| **Total Current Liabilities** | $7.97M | $8.15M | $8.49M | $10.63M | $6.84M | $4.77M | $5.34M | $6.06M | $4.67M | $4.52M |
| Long-Term Debt | -- | -- | -- | -- | -- | -- | $900K | -- | -- | -- |
| Deferred Revenue (Non-Current) | $35.00M | $35.00M | $35.00M | $35.00M | -- | -- | -- | -- | -- | -- |
| **Total Non-Current Liabilities** | $35.97M | $35.99M | $36.57M | $37.08M | $3.0K | $311K | $682K | $13K | $0 | $0 |
| **Total Liabilities** | $43.94M | $44.14M | $45.07M | $47.71M | $6.84M | $5.08M | $6.03M | $6.08M | $4.67M | $4.52M |
| **Total Debt (incl. Leases)** | $1.69M | $1.57M | $2.11M | $2.58M | $310K | $427K | $1.19M | $16K | -- | -- |
| Common Stock | $31K | $31K | $28K | $26K | $22K | $18K | $5.0K | $116K | $80K | $56K |
| Retained Earnings | -$409.7M | -$375.8M | -$337.6M | -$288.8M | -$255.7M | -$231.0M | -$208.8M | -$186.9M | -$163.2M | -$136.6M |
| Accumulated Other Comp. Income | -$20K | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **Total Stockholders' Equity** | $7.83M | $32.76M | $36.38M | $66.48M | $73.55M | $61.32M | $5.64M | $8.81M | $13.67M | $18.01M |
| Total Equity | $7.83M | $32.76M | $36.38M | $66.48M | $73.55M | $61.32M | $5.64M | $8.81M | $13.67M | $18.01M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $28.68M | $36.47M | $42.13M | $48.00M | $53.39M | $59.93M | $65.33M | $72.90M |
| **Cash & Short-Term Investments** | $28.68M | $36.47M | $42.13M | $48.00M | $53.39M | $59.93M | $65.33M | $72.90M |
| Other Current Assets | -- | -- | -- | $168K | -- | -- | -- | $357K |
| **Total Current Assets** | $29.49M | $37.74M | $43.26M | $49.38M | $54.37M | $61.03M | $66.46M | $74.51M |
| Property, Plant & Equipment, Net | $1.45M | $700K | $268K | $295K | $226K | $271K | $317K | $364K |
| **Total Non-Current Assets** | $2.97M | $2.42M | $2.18M | $2.39M | $1.78M | $1.99M | $2.19M | $2.39M |
| **Total Assets** | $32.47M | $40.16M | $45.44M | $51.77M | $56.15M | $63.02M | $68.65M | $76.90M |
| **Total Current Liabilities** | $7.37M | $9.26M | $7.35M | $7.97M | $6.83M | $8.31M | $7.11M | $8.15M |
| Deferred Revenue (Non-Current) | -- | -- | $35.00M | $35.00M | $35.00M | $35.00M | $35.00M | $35.00M |
| **Total Non-Current Liabilities** | $510K | $595K | $35.78M | $35.97M | $35.53M | $35.69M | $35.84M | $35.99M |
| **Total Liabilities** | $7.88M | $9.86M | $43.13M | $43.94M | $42.37M | $44.00M | $42.95M | $44.14M |
| **Total Debt (incl. Leases)** | $1.16M | $1.34M | $1.52M | $1.69M | $1.14M | $1.29M | $1.43M | $1.57M |
| Common Stock | $31K | $31K | $31K | $31K | $31K | $31K | $31K | $31K |
| Retained Earnings | -$393.2M | -$387.3M | -$415.2M | -$409.7M | -$403.8M | -$398.6M | -$391.8M | -$375.8M |
| Accumulated Other Comp. Income | -$70K | -$60K | -$39K | -$20K | -- | -- | -- | -- |
| **Total Stockholders' Equity** | $24.59M | $30.30M | $2.30M | $7.83M | $13.78M | $19.01M | $25.69M | $32.76M |
| Total Equity | $24.59M | $30.30M | $2.30M | $7.83M | $13.78M | $19.01M | $25.69M | $32.76M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$33.89M | -$38.24M | -$48.82M | -$33.02M | -$24.77M | -$22.21M | -$21.90M | -$23.65M | -$26.60M | -$24.32M |
| Depreciation & Amortization | $173K | $197K | $207K | $699K | $524K | $447K | $420K | $51K | $56K | $78K |
| Stock-Based Compensation | $9.19M | $5.29M | $3.84M | $2.79M | $1.69M | $1.25M | $1.29M | $1.80M | $3.49M | $4.30M |
| **Operating Cash Flow** | -$24.58M | -$33.07M | -$47.34M | $8.64M | -$20.87M | -$21.62M | -$21.46M | -$20.57M | -$21.55M | -$20.79M |
| Capital Expenditure | -$104K | -$11K | -$153K | -$366K | -$133K | -$253K | -$64K | -$96K | -$25K | -$60K |
| **Free Cash Flow** | -$24.68M | -$33.08M | -$47.49M | $8.28M | -$21.00M | -$21.87M | -$21.53M | -$20.67M | -$21.58M | -$20.85M |
| Purchases of Investments | -- | -- | -- | -- | -- | -- | -- | -- | -- | -$50K |
| **Investing Cash Flow** | -$104K | -$11K | -$153K | -$366K | -$133K | -$253K | -$64K | -$96K | -$25K | -$110K |
| Common Stock Issued | -- | $29.25M | $14.61M | $23.16M | $35.30M | $76.59M | $15.93M | $16.98M | $18.81M | $16.02M |
| **Financing Cash Flow** | -$217K | $29.32M | $14.87M | $23.11M | $35.22M | $76.18M | $17.11M | $16.98M | $18.81M | $15.78M |
| **Net Change in Cash** | -$24.89M | -$3.76M | -$32.62M | $31.39M | $14.22M | $54.31M | -$4.41M | -$3.69M | -$2.76M | -$5.12M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$5.84M | $27.90M | -$5.52M | -$5.94M | -$5.13M | -$6.88M | -$15.94M | -$6.65M |
| Depreciation & Amortization | $218K | $432K | $29K | -$442K | $206K | $362K | $47K | -$410K |
| Stock-Based Compensation | $136K | $118K | $11K | $10K | $109K | $197K | $8.87M | $1.20M |
| **Operating Cash Flow** | -$7.02M | -$5.18M | -$5.87M | -$5.29M | -$6.33M | -$5.39M | -$7.57M | -$5.75M |
| Capital Expenditure | -$770K | -$478K | -$2.0K | -- | -- | -- | -- | $0 |
| **Free Cash Flow** | -$7.79M | -$5.66M | -$5.87M | -- | -- | -- | -- | -$5.75M |
| **Investing Cash Flow** | -$770K | -$478K | -$2.0K | -- | -- | -- | -- | $0 |
| Common Stock Issued | -- | -- | -- | -- | -- | -- | -- | -$1.0K |
| **Financing Cash Flow** | -$3.0K | -$2.0K | -$3.0K | -$3.0K | -$209K | -$3.0K | -$2.0K | -$3.0K |
| **Net Change in Cash** | -$7.79M | -$5.66M | -$5.86M | -$5.39M | -$6.53M | -$5.39M | -$7.58M | -$5.75M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Gross Margin** | -- | -- | -- | -- | 21.3% | -- | -- | -- | -- | -- |
| **Operating Margin** | -40274.4% | -- | -64098.8% | -3311.1% | -2182.2% | -- | -- | -- | -- | -- |
| **Net Profit Margin** | -37652.2% | -- | -60269.1% | -3205.5% | -2165.6% | -- | -- | -- | -- | -- |
| Return on Equity (ROE) | -432.6% | -116.7% | -134.2% | -49.7% | -33.7% | -36.2% | -388.0% | -268.4% | -194.6% | -135.1% |
| Return on Assets (ROA) | -65.5% | -49.7% | -59.9% | -28.9% | -30.8% | -33.5% | -187.7% | -158.9% | -145.1% | -108.0% |
| Current Ratio | 6.20x | 9.14x | 9.21x | 10.44x | 11.66x | 13.62x | 1.89x | 2.36x | 3.82x | 4.95x |
| Quick Ratio | 6.02x | 8.95x | 9.03x | 10.25x | 11.38x | 13.33x | 1.73x | 2.26x | 3.73x | 4.54x |
| Debt to Equity | 0.22x | 0.05x | 0.06x | 0.04x | 0.00x | 0.01x | 0.21x | 0.00x | -- | -- |
| **Revenue Growth (YoY)** | -- | -- | -92.1% | -10.0% | -- | -- | -- | -- | -- | -- |
| Operating Cash Flow Growth (YoY) | -- | -- | -647.6% | -- | -- | -- | -- | -- | -- | -- |
| Free Cash Flow Growth (YoY) | -- | -- | -673.7% | -- | -- | -- | -- | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | 43.1% | 37.3% | -1018.7% | -432.6% | -251.0% | -215.8% | -177.1% | -116.7% |
| Return on Assets (ROA) | 32.6% | 28.2% | -51.7% | -65.5% | -61.6% | -65.1% | -66.3% | -49.7% |
| Current Ratio | 4.00x | 4.08x | 5.89x | 6.20x | 7.96x | 7.34x | 9.35x | 9.14x |
| Quick Ratio | 3.89x | 3.94x | 5.73x | 6.02x | 7.81x | 7.21x | 9.19x | 8.95x |
| Debt to Equity | 0.05x | 0.04x | 0.66x | 0.22x | 0.08x | 0.07x | 0.06x | 0.05x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
